stockrow
Friday 6 November 2026
Export CNXU’s income statement to Excel — free account
Conexeu Sciences Inc.
CNXU Healthcare Biotechnology
- EPS
- −214.9%
- Free cash flow
- −1,084.3%
Quarter to July 2026, against a year earlier
2.09
0.13
−5.86%
Follow CNXU
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jul ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 140 | 140 | 140 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | 0 | (4) | (14) | +731.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | 0 | (4) | (14) | +731.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (0.07) | (0.31) | (0.62) | +342.8% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.03) | (0.13) | (0.39) | +294.3% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.03) | (0.13) | (0.39) | +298.8% | ||||||
| Book value | — | — | — | — | — | — | — | — | 0.01 | 0.58 | 0.22 | +4,024.8% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 7 | 13 | 20 | +87.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | 0 | (2) | (11) | +640.9% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | 0 | (2) | (11) | +649.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 0 | 7 | 5 | +112,954.0% | |||||
| Net debt | — | — | — | — | — | — | — | — | 0 | (5) | (2) | +1,436.6% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 0 | 7 | 6 | +7,639.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (95.43) | (354.37) | (95.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (98.33) | (234.60) | (98.3) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (105.36) | (458.40) | (105.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Conexeu Sciences Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology, Inc. | $66.3M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| CNXU Conexeu Sciences Inc. | $65.4M | — (loss-making) | — | — | n/m | −1,084.33% (below 0%: shrinking) | — | 0.00% | |
| MAIA MAIA Biotechnology, Inc. | $64.2M | — (loss-making) | — | — | n/m | −63.23% (below 0%: shrinking) | — | 0.00% | Compare |
| CING Cingulate Inc. | $61.7M | — (loss-making) | — | — | n/m | −24.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FBIO Fortress Biotech, Inc. | $61.4M | 0.6× | 0.8× | +14.04% (above 0%: growing) | n/m | −115.37% (below 0%: shrinking) | 67.18% | (53.46%) | Compare |
| TENX Tenax Therapeutics, Inc. | $61.0M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $61.2M | — | — | −14.05% | — | −70.87% | 25.27% | 0.00% |